A randomized phase II study of bevacizumab (NSC 704865) and gemcitabine in combination with either cetuximab (NSC 714692) or OSI 774 (NSC 718781) [erlotinib] in patients with advanced pancreatic cancer

Trial Profile

A randomized phase II study of bevacizumab (NSC 704865) and gemcitabine in combination with either cetuximab (NSC 714692) or OSI 774 (NSC 718781) [erlotinib] in patients with advanced pancreatic cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Erlotinib (Primary) ; Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top